FDA Calls Medicare ESA Coverage Decision “Generally Consistent” With Labeling
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA acknowledges confusion with dosing recommendations that it aims to clarify in revised labeling, agency advises Reps. Waxman and Stark.